Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib Plus Aromatase Inhibitor in HR+/HER2- Early Breast Cancer With Residual Disease
NCT07400523Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ribociclib in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Started Feb 2026; status: recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07400523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400523.